OX40

Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Monday, March 4, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Allergy, Investigational New Drug, PD, Research, YTE, Hereditary angioedema, Investment, Atopic dermatitis, Richard Driehaus, Safety, OX40, HAE, Therapy, Pharmacokinetics, Patient, Pharmaceutical industry

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.
  • The trial is evaluating safety and tolerability, changes in HAE attack rate, pharmacokinetics (PK), pharmacodynamics (PD), and quality-of-life assessments.
  • Pending proof-of-concept results from the ALPHA-STAR trial, Astria expects to progress directly to a pivotal Phase 3 program which is anticipated to initiate in the first quarter of 2025.
  • Cash Position: As of December 31, 2023, Astria had cash, cash equivalents and short-term investments of $246.5 million, compared to $188.8 million as of September 30, 2023.

HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership

Retrieved on: 
Friday, February 2, 2024
Option, Partnership, BTK, Alopecia areata, SAD, Exercise, Patient, Atopic dermatitis, OX40, HKEX, Pharmaceutical industry

As part of the partnership, HUTCHMED granted Inmagene exclusive options to multiple drug candidates solely for the treatment of immunological diseases.

Key Points: 
  • As part of the partnership, HUTCHMED granted Inmagene exclusive options to multiple drug candidates solely for the treatment of immunological diseases.
  • Since the execution of the Option agreement, Inmagene has funded and led two of these candidates, IMG-004 and IMG-007, to clinical development.
  • The success of this strategic partnership provides further validation of HUTCHMED’s in-house R&D engine and our collaborative approach to developing some of our innovative drug candidates.
  • We look forward to continuing our partnership with Inmagene and seeing the impact these drug candidates could have for patients with immunological diseases.”

Astria Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update

Retrieved on: 
Monday, November 13, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Webcast, Interest, Plasma kallikrein, Safety, D, Therapy, First Nations Summit, IND, Investment, PD, Experiment, Patient, Allergy, Journal, Atopic dermatitis, Hereditary angioedema, Investigational New Drug, HAE, Half-life, YTE, OX40, Pharmacodynamics, ACAAI, Pharmaceutical industry, Cryptocurrency, Asteria, Pharmacology

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.
  • We now expect to deliver initial proof-of-concept results in Q1 2024 from the Phase 1b/2 ALPHA-STAR trial in HAE patients.
  • STAR-0215 achieved potentially therapeutic levels in less than one day and showed an estimated half-life of up to 127 days.
  • Additional preclinical results were shared in the Journal of Pharmacology and Experimental Therapeutics that support STAR-0215’s potential as a best-in-class plasma kallikrein inhibitor.

Astria Therapeutics Announces Exclusive Worldwide License Agreement with Ichnos Sciences for OX40 Portfolio

Retrieved on: 
Wednesday, October 11, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, YTE, HAE, Allergy, Atopic dermatitis, IND, Safety, Half-life, Therapy, OX40, Hereditary angioedema, Pathology, PD, AD, Investigational New Drug, Patient, Vaccine, Pharmaceutical industry, Asteria

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it has entered into a worldwide exclusive license agreement with Ichnos Sciences for an OX40 portfolio to be developed for the potential treatment of atopic dermatitis (AD) and potentially for other allergic and immunological diseases.

Key Points: 
  • Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it has entered into a worldwide exclusive license agreement with Ichnos Sciences for an OX40 portfolio to be developed for the potential treatment of atopic dermatitis (AD) and potentially for other allergic and immunological diseases.
  • Astria plans to develop the lead candidate, called STAR-0310, a monoclonal antibody OX40 antagonist that incorporates YTE half-life extension technology, for the treatment of AD.
  • Astria also sees an opportunity with STAR-0310 for potential expansion into additional indications.
  • Based on the inclusion of the YTE modification, Astria believes STAR-0310 has the potential to be dosed once every two to three months.

ICHNOS SCIENCES ENTERS LICENSING AGREEMENT FOR OX40 ANTAGONIST MONOCLONAL ANTIBODY PORTFOLIO WITH ASTRIA THERAPEUTICS

Retrieved on: 
Wednesday, October 11, 2023
YTE, Immunoglobulin G, Allergy, Inflammation, Atopic dermatitis, Disease, Patient, Therapy, AD, OX40, Pharmaceutical industry, Vaccine, Trace fossil classification

NEW YORK, Oct. 11, 2023 /PRNewswire/ -- Ichnos Sciences, a global clinical-stage biotechnology company developing innovative multispecific antibodies for oncology, today announced that the company has entered into an exclusive worldwide licensing agreement for its OX40 antagonist monoclonal antibody portfolio with Astria Therapeutics, a biopharmaceutical company developing therapies for rare allergic and immunological diseases. With the execution of this agreement, Ichnos has successfully licensed its two assets for inflammatory and immunological diseases, a key milestone in the company's prioritization of its pipeline of oncology drug candidates.

Key Points: 
  • Astria Therapeutics is granted global rights to develop and commercialize OX40 portfolio, comprised of Telazorlimab and its follow-on molecules, for use in inflammatory and immune diseases.
  • NEW YORK, Oct. 11, 2023 /PRNewswire/ -- Ichnos Sciences, a global clinical-stage biotechnology company developing innovative multispecific antibodies for oncology, today announced that the company has entered into an exclusive worldwide licensing agreement for its OX40 antagonist monoclonal antibody portfolio with Astria Therapeutics, a biopharmaceutical company developing therapies for rare allergic and immunological diseases.
  • Telazorlimab is a novel, humanized IgG1 monoclonal antibody that targets OX40 on T cells responsible for inflammation and immunity diseases.
  • "We are looking forward to building on the foundational work that Ichnos has done with their OX40 portfolio," said Jill Milne, Ph.D., co-founder and CEO of Astria Therapeutics.

BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab)

Retrieved on: 
Tuesday, September 19, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Monoclonal antibody, BGNE, Cancer, Quality of life, SSE, OX40, LAG3, Patient, Medicine, European, Entrepreneurship, PD-L1, Safety, Tislelizumab, Pharmaceutical industry, BeiGene, HPK1, Novartis

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that it has entered into an agreement with Novartis to regain worldwide rights to develop, manufacture, and commercialize TEVIMBRA (tislelizumab).

Key Points: 
  • BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that it has entered into an agreement with Novartis to regain worldwide rights to develop, manufacture, and commercialize TEVIMBRA (tislelizumab).
  • “BeiGene will continue to work with Novartis on development, regulatory and manufacturing priorities.
  • BeiGene has agreed to provide Novartis with ongoing clinical supply of TEVIMBRA to support its clinical trials.
  • Under the agreement, Novartis was responsible for regulatory submissions and had the right to commercialize in these licensed countries following regulatory approval.

Fierce Biotech Names HiFiBiO Therapeutics a “Fierce 15” Biotech Company of 2023

Retrieved on: 
Monday, August 28, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, TNFR2, Probability, Therapy, Face, Health care, Multimedia, Immunotherapy, Doctor of Philosophy, Creativity, BTLA, OX40, Patient, Pharmaceutical industry

HiFiBiO Therapeutics, a clinical stage global biotech company focusing on improving patient lives with single cell precision, today announced that Fierce Biotech has named it as one of 2023’s “Fierce 15” biotechnology companies.

Key Points: 
  • HiFiBiO Therapeutics, a clinical stage global biotech company focusing on improving patient lives with single cell precision, today announced that Fierce Biotech has named it as one of 2023’s “Fierce 15” biotechnology companies.
  • View the full release here: https://www.businesswire.com/news/home/20230828615800/en/
    “HiFiBiO Therapeutics is at the forefront of harnessing single-cell insights to bring innovative immunomodulatory therapeutics into the clinic,” remarked Liang Schweizer, PhD, Founder, Chairperson, and CEO of HiFiBiO Therapeutics.
  • Since 2017, HiFiBiO Therapeutics has built a sustainable pipeline targeting key mechanisms of immune modulation, with eight clinical candidates discovered, mainly across oncology and autoimmune diseases.
  • “For the past 21 years, we have assessed hundreds of early-stage companies for inclusion in the 'Fierce 15' special report.

BeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio

Retrieved on: 
Thursday, May 25, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Abstract (summary), Rituximab, Obinutuzumab, BGNE, EU, Doctor of Philosophy, Hepatocellular carcinoma, Lymphoid leukemia, NA, Lenalidomide, OS, Trae tha Truth, Head, Toxicity, Multimedia, BCLC, Lung cancer, ASCO, PLR, Incidence, SSE, OX40, American Society of Clinical Oncology, Patient, Sorafenib, NLR, Annual general meeting, Bone marrow, Abstract, Society, ORR, Tislelizumab, Pharmaceutical industry, Vaccine, Flour, BeiGene

These results include data for BeiGene’s cornerstone therapies, BRUKINSA® (zanubrutinib) and tislelizumab, as well as early results for BeiGene’s OX40 agonist and BCL-2 inhibitor.

Key Points: 
  • These results include data for BeiGene’s cornerstone therapies, BRUKINSA® (zanubrutinib) and tislelizumab, as well as early results for BeiGene’s OX40 agonist and BCL-2 inhibitor.
  • These results will be presented on Monday, June 5, as poster presentations from 8:00-11:00 a.m. CT. (Abstracts #4082 and #4083).
  • BGB-11417 monotherapy also showed promising initial efficacy results in R/R chronic lymphocytic leukemia/small lymphocytic lymphoma, with patients achieving responses at lower dose levels.
  • These results will be presented on Monday, June 5, as a poster presentation from 8:00-11:00 a.m. CT (Abstract #7558).

Avalo Announces Appointment of Michael Croft, Ph.D. and Jeff Edelson, M.D. to its Scientific Advisory Board

Retrieved on: 
Monday, May 22, 2023
Inflammation, SAB, COPD, GSK, La Jolla Institute for Immunology, Asthma, Drug development, Therapy, TNF, Cell, Cancer, Autoimmunity, Research, Edelson, Infection, Immunotherapy, Sanofi, BTLA, OX40, Protein, Publication, Sanford Burnham Prebys Medical Discovery Institute, Patient, Autoimmune disease, Immunology, Safety, Medical device, Pharmaceutical industry, Vaccine

WAYNE, Pa. and ROCKVILLE, Md., May 22, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced the appointment of Dr. Michael Croft and Dr. Jeff Edelson to the company’s Scientific Advisory Board (SAB).

Key Points: 
  • WAYNE, Pa. and ROCKVILLE, Md., May 22, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced the appointment of Dr. Michael Croft and Dr. Jeff Edelson to the company’s Scientific Advisory Board (SAB).
  • His work has resulted in numerous publications in prestigious scientific journals, earning him international recognition and numerous accolades for his scientific achievements.
  • Throughout his career, Dr. Edelson has been widely published in esteemed scientific journals, sharing his research findings and insights with the scientific community.
  • He has also been actively involved in professional organizations and has served on advisory boards and committees related to basic research and drug development.

BeiGene to Highlight Broad Oncology Portfolio at the 2023 ASCO Annual Meeting

Retrieved on: 
Wednesday, April 26, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Docetaxel, Apoptosis, Pivotal, Tislelizumab, Obinutuzumab, Pharmacokinetics, OX40, Cholangiocarcinoma, Patient, Hepatocellular carcinoma, Sorafenib, Safety, Medical imaging, Vaccine

Results from the Pivotal Phase 2b HERIZON-BTC-01 Study: Zanidatamab in Previously-treated HER2 amplified Biliary Tract Cancer

Key Points: 
  • Results from the Pivotal Phase 2b HERIZON-BTC-01 Study: Zanidatamab in Previously-treated HER2 amplified Biliary Tract Cancer
    A phase 1 study of the OX40 agonist, BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors
    Zanidatamab, a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy for patients with advanced HER2-positive breast cancer: updated results from a Phase Ib/II study
    Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: the RATIONALE-301 European/North American subgroup
    A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies
    Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study